Valo Health has finished enrolling subjects in its Phase II Spectra clinical trial of OPL-0401, an investigational oral treatment for diabetic retinopathy (DR). The randomised, placebo-controlled trial is designed to assess the potential benefits of the therapy in subjects with moderately severe or severe non-proliferative DR (NPDR) The company expects to report top-line data from the trial before the end of this year. View profiles in store Company Profile – free sample Thank you!